First patient treated in the EffiKIR trial
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the first...
Update on clinical trials with IPH2101 in Multiple Myeloma
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, updates on four early clinical...
Innate Pharma announces revenue for the first nine months of 2012 and updates on its cash position
Revenue of 8.0 million euros Cash position as at September 30, 2012 of 32.3 million euros Change to the supervisory board Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity...
Innate Pharma to meet its retail investors at Actionaria on November 23 & 24
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, announces its second participation to...
First clinical trial with IPH2102/BMS-986015 sponsored by Bristol-Myers Squibb announced
A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the...
Results of IPH2101 Phase I trial in AML published in BLOOD
23 patients, median age 71, in first complete remission, received escalating doses of IPH2101 Conclusions support the rationale behind the recently announced multicentre, double-blind, Phase II trial...
Financial results for the first half of 2012
Three-year cash horizon resulting from collaboration and licensing agreement with Bristol-Myers Squibb Significant advance of the IPH21 program with the regulatory authorization to start the first...
Innate Pharma receives regulatory authorization to start randomized Phase II trial with IPH2102 in Acute Myeloid Leukemia
First randomized Phase II trial of the anti-KIR antibody IPH2102 Led by French Cooperative Groups in AML and sponsored by Innate Pharma Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 –...
All proposed resolutions at the Annual General Meeting of June 28, 2012 were voted according to management’s recommendations
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that its Annual General Meeting (“AGM”) took place on June 28, 2012, in Marseilles, France. A number of 21,148,778 votes were expressed out...
Innate Pharma to hold its Annual General Meeting of Shareholders on June 28, 2012, in Marseilles, France
Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on June 28, 2012, at 9:30 am in its headquarters, 117 avenue de Luminy, F-13009...